- Compugen to Present at Upcoming Antibody Industrial Symposium
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
- Compugen Reports First Quarter 2024 Results
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
More ▼
Key statistics
On Monday, Compugen Ltd (CGEN:NAQ) closed at 1.91, -36.97% below its 52-week high of 3.03, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.78 |
---|---|
High | 2.05 |
Low | 1.76 |
Bid | 1.86 |
Offer | 1.97 |
Previous close | 1.91 |
Average volume | 323.51k |
---|---|
Shares outstanding | 89.53m |
Free float | 84.72m |
P/E (TTM) | -- |
Market cap | 171.00m USD |
EPS (TTM) | -0.1893 USD |
Data delayed at least 15 minutes, as of Jul 15 2024 21:00 BST.
More ▼